Lipopolysaccharide (LPS)-induced liver injury is the main factor in
acute liver failure. The current study aims to investigate the protection of
limonin, an
antioxidant compound from citrus fruit, against LPS-induced liver toxicity and elucidate the potential mechanisms. We found that
limonin elevated cell viability and reduced LDH release in LPS-treated HepG2 cells.
Limonin also inhibited LPS-induced pyroptosis by inhibiting membrane
rupture, reducing ROS generation, and decreasing gasdermin D activation. Moreover,
limonin inhibited the formation of a
NOD-like receptor protein 3 (NLRP3)/Apoptosis-associated speck-like
protein containing a CARD (ASC) complex by reducing the related
protein expression and the colocalization cytosolic of NLRP3 and caspase-1 and then suppressed IL-1β maturation. Ultimately, we established LPS-induced hepatotoxicity in vivo by using C57BL/6 mice administrated LPS (10 mg/kg) intraperitoneally and
limonin (50 and 100 mg/kg) orally. We found that
limonin dereased the serum ALT and AST activity and LDH release and increased the hepatic GSH amount in LPS-treated mice. Additionally, the liver histological evaluation revealed that
limonin protects against LPS-induced liver damage. We further demonstrated that
limonin ameliorated LPS-induced hepatotoxicity by inhibiting pyroptosis via the NLRP3/gasdermin D signaling pathway. In summary, this study uncovered the mechanism whereby
limonin mitigated LPS-induced hepatotoxicity and documented that
limonin might be a promising candidate
drug for LPS-induced hepatotoxicity.